NCT00104884 2023-06-28
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
Clinical Trials
3 trialsNCT00106431 2019-10-30
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Celgene
Phase 2 Completed
NCT00007345 2017-05-16
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed